Single nucleotide polymorphism (SNP) targeting therapies for the treatment of huntington'S disease
US8987222B2 · kind B2 · utility
23Cited by
0References
21Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 8, 2010 |
| Grant date | Mar 24, 2015 |
| Priority date | — |
| Expiry date | Apr 16, 2030 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2320/34
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to the discovery of (SNPs) significantly associated with Huntington's disease (HD). The present invention utilizes RNA silencing technology (e.g. RNAi) against such SNPs optimally combined with select additional SNP targeting silencing agents, thereby resulting in an effective treatment of significantly-sized patient populations. Silencing agents having enhanced discriminatory properties are also featured.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.